Jeremie Prevost
Overview
Explore the profile of Jeremie Prevost including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
92
Citations
2661
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Chen Y, Prevost J, Ullah I, Romero H, Lisi V, Tolbert W, et al.
iScience
. 2022 Dec;
26(1):105783.
PMID: 36514310
Neutralizing antibodies (NAbs) hold great promise for clinical interventions against SARS-CoV-2 variants of concern (VOCs). Understanding NAb epitope-dependent antiviral mechanisms is crucial for developing vaccines and therapeutics against VOCs. Here...
22.
Matsumoto K, Kuwata T, Tolbert W, Richard J, Ding S, Prevost J, et al.
J Virol
. 2022 Dec;
97(1):e0163822.
PMID: 36511698
Small CD4-mimetic compound (CD4mc), which inhibits the interaction between gp120 with CD4, acts as an entry inhibitor and induces structural changes in the HIV-1 envelope glycoprotein trimer (Env) through its...
23.
Prevost J, Anand S, Rajashekar J, Zhu L, Richard J, Goyette G, et al.
Cell Rep
. 2022 Nov;
41(6):111624.
PMID: 36351384
Non-neutralizing antibodies (nnAbs) can eliminate HIV-1-infected cells via antibody-dependent cellular cytotoxicity (ADCC) and were identified as a correlate of protection in the RV144 vaccine trial. Fc-mediated effector functions of nnAbs...
24.
Gong S, Ding S, Benlarbi M, Chen Y, Vezina D, Marchitto L, et al.
Viruses
. 2022 Oct;
14(10).
PMID: 36298733
SARS-CoV-2 continues to infect millions of people worldwide. The subvariants arising from the variant-of-concern (VOC) Omicron include BA.1, BA.1.1, BA.2, BA.2.12.1, BA.4, and BA.5. All possess multiple mutations in their...
25.
Benlarbi M, Laroche G, Fink C, Fu K, Mulloy R, Phan A, et al.
iScience
. 2022 Oct;
25(11):105316.
PMID: 36254158
The severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) spike glycoprotein (S) binds to angiotensin-converting enzyme 2 (ACE2) to mediate membrane fusion via two distinct pathways: 1) a surface, serine protease-dependent or...
26.
Nayrac M, Dube M, Sannier G, Nicolas A, Marchitto L, Tastet O, et al.
Cell Rep
. 2022 Jun;
39(13):111013.
PMID: 35732172
Spacing of BNT162b2 mRNA doses beyond 3 weeks raises concerns about vaccine efficacy. We longitudinally analyze B cell, T cell, and humoral responses to two BNT162b2 mRNA doses administered 16 ...
27.
Valcourt E, Manguiat K, Robinson A, Lin Y, Abe K, Mubarek S, et al.
Microbiol Spectr
. 2022 Jun;
10(4):e0055322.
PMID: 35730975
No abstract available.
28.
Boutin M, Vezina D, Ding S, Prevost J, Laumaea A, Marchitto L, et al.
mBio
. 2022 Apr;
13(3):e0057722.
PMID: 35475646
The heavily glycosylated HIV-1 envelope glycoprotein (Env) is the sole viral antigen present at the surface of virions and infected cells, representing the main target for antibody responses. The FDA-approved...
29.
Chatterjee D, Tauzin A, Marchitto L, Gong S, Boutin M, Bourassa C, et al.
Cell Rep
. 2022 Feb;
38(9):110429.
PMID: 35216664
Continuous emergence of SARS-CoV-2 variants of concern (VOCs) is fueling the COVID-19 pandemic. Omicron (B.1.1.529) rapidly spread worldwide. The large number of mutations in its Spike raise concerns about a...
30.
Beaudoin-Bussieres G, Chen Y, Ullah I, Prevost J, Tolbert W, Symmes K, et al.
Cell Rep
. 2022 Feb;
38(7):110368.
PMID: 35123652
Emerging evidence indicates that both neutralizing and Fc-mediated effector functions of antibodies contribute to protection against SARS-CoV-2. It is unclear whether Fc-effector functions alone can protect against SARS-CoV-2. Here, we...